Invention Grant
- Patent Title: Anti-CLDN6 antibody
- Patent Title (中): 抗CLDN6抗体
-
Application No.: US12735359Application Date: 2009-01-09
-
Publication No.: US09274119B2Publication Date: 2016-03-01
- Inventor: Hiroyuki Aburatani , Shuichi Tsutsumi , Kunihiro Nishimura , Hirofumi Sakumoto , Shigeto Kawai
- Applicant: Hiroyuki Aburatani , Shuichi Tsutsumi , Kunihiro Nishimura , Hirofumi Sakumoto , Shigeto Kawai
- Applicant Address: JP Tokyo JP Tokyo
- Assignee: THE UNIVERSITY OF TOKYO,CHUGAI SEIYAKU KABUSHIKI KAISHA
- Current Assignee: THE UNIVERSITY OF TOKYO,CHUGAI SEIYAKU KABUSHIKI KAISHA
- Current Assignee Address: JP Tokyo JP Tokyo
- Agency: Sughrue Mion, PLLC
- Priority: JP2008-004423 20080111
- International Application: PCT/JP2009/000082 WO 20090109
- International Announcement: WO2009/087978 WO 20090716
- Main IPC: C07K16/28
- IPC: C07K16/28 ; G01N33/574 ; A61K39/00
Abstract:
The present invention relates to an antibody binding to Claudin6 (CLDN6) expressed on a cell membrane. The antibody of the present invention recognizes human CLDN6 present in a native form on cell membrane surface and exhibits cytotoxicity through ADCC and/or CDC activities against cancer cell lines highly expressing human CLDN6. Moreover, the antibody of the present invention has cell growth inhibitory effect through conjugation with toxin on cancer cell lines highly expressing human CLDN6. The human CLDN6 is overexpressed in tumor tissues (lung adenocarcinoma, gastric cancer, and ovarian cancer), although its expression is not observed in normal tissues. Thus, the anti-CLDN6 antibody is expected to highly accumulate in tumors highly expressing human CLDN6 and can serve as a very effective antitumor agent.
Public/Granted literature
- US20110059469A1 ANTI-CLDN6 ANTIBODY Public/Granted day:2011-03-10
Information query
